North America FMD Vaccine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA FMD VACCINE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET APPLICATION COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 ECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.3 EPIDEMIOLOGY OF FOOT-AND-MOUTH DISEASE (FMD)

4.3.1 FMD INCIDENCE RATE BY SPECIES AND REGION

4.3.1.1 INCIDENCE BY SPECIES AND MORBIDITY BURDEN

4.3.1.2 PREVALENCE PATTERNS AND REGIONAL SEROTYPE DISTRIBUTION

4.3.2 VACCINATION COVERAGE RATE

4.4 MORTALITY AND MORBIDITY IMPACT

4.4.1 VACCINE COMPLIANCE AND PROGRAM ADHERENCE

4.4.2 DISEASE CONTAINMENT SUCCESS RATES

4.5 INDUSTRY INSIGHTS

4.5.1 MICRO AND MACRO ECONOMIC FACTORS

4.5.2 PENETRATION AND GROWTH PROSPECT MAPPING

4.5.3 KEY PRICING STRATEGIES

4.5.4 INTERVIEWS WITH SPECIALISTS

4.5.5 ANALYSIS AND RECOMMENDATION

4.6 COMPANY EVALUATION QUADRANT

4.7 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA FMD VACCINE MARKET

4.8 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE NORTH AMERICA FMD VACCINE MARKET

4.9 DISTRIBUTION OF PROJECTS BY SPECIES AND PHASE NORTH AMERICA FMD VACCINE MARKET

4.1 NORTH AMERICA CLINICAL TRIAL MARKET FOR NORTH AMERICA FMD VACCINE MARKET

4.11 HEALTHCARE TARIFFS IMPACT ANALYSIS

4.11.1 OVERVIEW

4.11.2 TARIFF STRUCTURES

4.11.2.1 NORTH AMERICA VS. REGIONAL TARIFF STRUCTURES

4.11.2.2 UNITED STATES: USDA/APHIS TARIFF POLICIES, ANIMAL HEALTH PROGRAM MODELS

4.11.2.2.1 EUROPEAN UNION: CROSS-BORDER TRADE REGULATIONS, SUBSIDY POLICIES

4.11.2.2.2 ASIA-PACIFIC: IMPORT AND EXPORT CONTROLS ON VETERINARY VACCINES

4.11.2.2.3 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION

4.11.3 PHARMACEUTICAL (VETERINARY BIOLOGICS) TARIFFS AND TRADE BARRIERS

4.11.3.1 IMPORT DUTIES ON VACCINES AND BIOLOGICALS

4.11.3.2 IMPACT ON AFFORDABILITY AND ACCESS IN RURAL AREAS

4.11.3.3 KEY TRADE AGREEMENTS AFFECTING ANIMAL HEALTH PRODUCT TARIFFS

4.11.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND FARMERS

4.11.4.1 COST BURDEN ON COMMERCIAL FARMS AND VETERINARIANS

4.11.4.2 EFFECT ON VACCINE AFFORDABILITY AND HERD COVERAGE

4.11.4.3 TARIFFS AND IMPACT ON ANIMAL TRADE/MOVEMENT

4.11.5 TRADE AGREEMENTS AND ANIMAL HEALTH TARIFFS

4.11.5.1 WTO REGULATIONS ON VETERINARY PRODUCTS

4.11.5.2 IMPACT OF TRADE WARS ON VACCINE SUPPLY CHAIN

4.11.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN TARIFF REDUCTION

4.11.6 IMPACT OF TARIFFS ON VETERINARY VACCINE COSTS & ACCESSIBILITY

4.11.7 IMPORTANCE OF TARIFFS IN THE ANIMAL HEALTH SECTOR

4.12 MARKETED VACCINE ANALYSIS

4.12.1 VACCINE BRAND & GENERIC NAME / ANTIGENIC STRAIN

4.12.2 INDICATION

4.12.3 PHARMACOLOGICAL CLASS OF THE VACCINE

4.12.4 PRIMARY INDICATION

4.12.5 MARKET STATUS

4.12.6 VACCINE TYPE (CONVENTIONAL, NEXT-GEN, ETC.)

4.12.7 DOSAGE FORM

4.12.8 DOSAGE AVAILABILITY

4.12.9 PACKAGING TYPE

4.12.10 ROUTE OF ADMINISTRATION

4.12.11 DOSING FREQUENCY

4.12.12 VACCINE INSIGHT

4.12.13 OVERVIEW OF DEVELOPMENT ACTIVITIES (APPROVALS, SAFETY, EFFICACY, MARKET EXCLUSIVITY)

4.12.13.1 FORECAST MARKET OUTLOOK

4.12.14 CROSS COMPETITION (BY STRAIN/VALENCY)

4.12.15 THERAPEUTIC PORTFOLIO

4.12.16 CURRENT DEVELOPMENT SCENARIO

4.13 PATENT ANALYSIS

4.13.1 PATENT QUALITY AND STRENGTH

4.13.2 COUNTRY PATENT LANDSCAPE

4.13.3 IP STRATEGY AND MANAGEMENT

4.13.4 LICENSING AND COLLABORATION

4.14 TOP ENTITIES BASED ON R&D GLANCE FOR NORTH AMERICA FMD VACCINE MARKET

4.15 MARKET ACCESS

4.15.1 10-YEAR MARKET FORECAST

4.15.2 CLINICAL TRIAL RECENT UPDATES

4.15.3 ANNUAL NEW VACCINE APPROVALS (OIE/REGIONAL AUTHORITIES)

4.15.4 LEADING MANUFACTURERS AND STRATEGIC DEALS

4.15.5 MAJOR VACCINE UPTAKE

4.15.6 CURRENT VACCINATION PRACTICES

4.15.7 IMPACT OF UPCOMING TECHNOLOGIES AND THERAPY

4.16 R & D ANALYSIS

4.16.1 COMPARATIVE ANALYSIS

4.16.2 VACCINE DEVELOPMENT LANDSCAPE

4.16.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

4.16.4 THERAPEUTIC ASSESSMENT

4.16.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

5 WAR-DRIVEN DISRUPTION IN VETERINARY VACCINE SUPPLY CHAINS, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES

5.1 SUPPLY CHAIN RESILIENCE

5.1.1 DIVERSIFICATION OF ANTIGEN AND ADJUVANT INGREDIENT SUPPLIERS

5.1.2 ESTABLISHMENT OF REGIONAL VETERINARY VACCINE MANUFACTURING HUBS

5.1.3 STRATEGIC STOCKPILING OF EMERGENCY VACCINE BANKS

5.1.4 DEVELOPMENT OF ALTERNATIVE COLD CHAIN LOGISTICS ROUTES

5.1.5 STRATEGIC PARTNERSHIPS WITH CONTRACT MANUFACTURERS (CDMOS)

5.1.6 EXPANSION OF VACCINE FILL-FINISH AND PACKAGING CAPACITIES

5.2 ENERGY & MANUFACTURING OPERATIONAL COST RISK

5.2.1 RISING ENERGY COSTS IN ANIMAL HEALTH PRODUCTION FACILITIES

5.2.2 INCREASED COSTS FOR BIOLOGICS RAW MATERIALS AND COMPONENTS

5.2.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES FOR VETERINARY PLANTS

5.2.4 ADOPTION OF ENERGY-EFFICIENT BIOPHARMA MANUFACTURING TECHNOLOGIES

5.2.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS MANUFACTURING

5.2.6 INTEGRATION OF RENEWABLE ENERGY IN VETERINARY VACCINE PLANTS

5.3 GEOGRAPHIC FOOTPRINT REASSESSMENT

5.3.1 EXPANSION OF VACCINE PRODUCTION IN POLITICALLY STABLE REGIONS

5.3.2 DIVERSIFICATION OF NORTH AMERICA VETERINARY VACCINE BASES

5.3.3 RELOCATION OF ANTIGEN PRODUCTION FACILITIES

5.3.4 EXPANSION OF MANUFACTURING IN EMERGING ANIMAL HEALTH MARKETS

5.3.5 ESTABLISHMENT OF REGIONAL VETERINARY VACCINE DISTRIBUTION HUBS

5.4 SCENARIO PLANNING & RISK MANAGEMENT

5.4.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS FOR OUTBREAKS

5.4.2 MULTI-SOURCE PROCUREMENT STRATEGIES FOR KEY VACCINE INGREDIENTS

5.4.3 GOVERNMENT AND ANIMAL HEALTH AUTHORITY COLLABORATIONS

5.4.4 CRISIS-RESPONSE VACCINE DEPLOYMENT NETWORKS

5.4.5 DEPLOYMENT OF SUPPLY CHAIN ANALYTICS IN VACCINE DISTRIBUTION

5.5 CASH & FINANCIAL PROTECTION

5.5.1 STRENGTHENING CAPITAL RESERVES FOR MANUFACTURING EXPANSION

5.5.2 DIVERSIFICATION OF PRODUCT PORTFOLIOS AND REVENUE STREAMS

5.5.3 INVESTMENTS IN DOMESTIC VACCINE MANUFACTURING INFRASTRUCTURE

5.5.4 GOVERNMENT INCENTIVES FOR ANIMAL HEALTH PRODUCTION

5.5.5 LONG-TERM PROCUREMENT AGREEMENTS WITH GOVERNMENTS AND ORGANIZATIONS

5.6 DATA PROTECTION

5.6.1 DATA PROTECTION FRAMEWORKS FOR ANIMAL HEALTH R&D AND MANUFACTURING

5.6.2 PROTECTION OF VETERINARY CLINICAL TRIAL AND FIELD DATA

5.6.3 SECURE CLOUD INFRASTRUCTURE FOR VACCINE DATA MANAGEMENT

5.6.4 AI-DRIVEN THREAT DETECTION IN RESEARCH AND SUPPLY NETWORKS

5.6.5 COMPLIANCE WITH NORTH AMERICA ANIMAL HEALTH DATA REGULATIONS AND GXP STANDARDS

6 REGULATORY FRAMEWORK FOR FMD VACCINES

6.1 REGULATORY APPROVAL PROCESS FOR FMD VACCINES

6.1.1 INTERNATIONAL NORMS AND STANDARDS FOR FMD VACCINES

6.1.2 BIOSAFETY AND CONTAINMENT REGULATIONS

6.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

6.3 REGULATORY APPROVAL PATHWAYS FOR VETERINARY VACCINES

6.4 LICENSING AND REGISTRATION REQUIREMENTS

6.5 POST-MARKETING SURVEILLANCE FOR VETERINARY PRODUCTS

6.6 GOOD MANUFACTURING PRACTICES (GMP) GUIDELINES FOR ANIMAL HEALTH

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWTH IN NORTH AMERICA LIVESTOCK POPULATION

7.1.2 RISING PREVALENCE OF FMD OUTBREAKS

7.1.3 GROWING GOVERNMENT VACCINATION PROGRAMS

7.1.4 INCREASING AWARENESS OF ANIMAL HEALTH AND BIOSECURITY

7.2 RESTRAINTS

7.2.1 LIMITED COLD CHAIN INFRASTRUCTURE

7.2.2 VACCINE HESITANCY AND FIELD CHALLENGES

7.3 OPPORTUNITIES

7.3.1 INTEGRATION OF DIGITAL VETERINARY SURVEILLANCE SYSTEMS

7.3.2 RISING ADOPTION OF MULTIVALENT AND HIGH-POTENCY VACCINES

7.3.3 EMERGING MARKETS WITH HIGH LIVESTOCK POPULATIONS

7.4 CHALLENGES

7.4.1 VIRAL MUTATION AND SEROTYPE VARIABILITY

7.4.2 ENFORCEMENT OF VACCINATION REGULATIONS

8 NORTH AMERICA FMD VACCINE MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 CONVENTIONAL VACCINES

8.3 NEXT-GENERATION / ADVANCED VACCINES

8.4 OTHERS

8.5 NORTH AMERICA FMD VACCINE MARKET, BY VACCINE TYPE, 2018-2033 (THOUSAND UNITS)

8.5.1 CONVENTIONAL VACCINES

8.5.2 NEXT-GENERATION / ADVANCED VACCINES

8.5.3 OTHERS

9 NORTH AMERICA FMD VACCINE MARKET, BY TYPE

9.1 OVERVIEW

9.2 INACTIVATED (KILLED) VACCINES

9.3 LIVE ATTENUATED VACCINES

9.4 NORTH AMERICA CONVENTIONAL VACCINES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.4.1 ASIA-PACIFIC

9.4.2 EUROPE

9.4.3 NORTH AMERICA

9.4.4 SOUTH AMERICA

9.4.5 MIDDLE EAST AND AFRICA

9.5 NORTH AMERICA NEXT-GENERATION / ADVANCED VACCINES IN FMD VACCINE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 RECOMBINANT VECTOR-BASED VACCINES

9.5.2 VIRUS-LIKE PARTICLE (VLP) VACCINES

9.5.3 SUBUNIT VACCINES

9.5.4 OTHERS

9.6 NORTH AMERICA CONVENTIONAL VACCINES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.6.1 ASIA-PACIFIC

9.6.2 EUROPE

9.6.3 NORTH AMERICA

9.6.4 SOUTH AMERICA

9.6.5 MIDDLE EAST AND AFRICA

9.7 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.7.1 ASIA-PACIFIC

9.7.2 EUROPE

9.7.3 NORTH AMERICA

9.7.4 SOUTH AMERICA

9.7.5 MIDDLE EAST AND AFRICA

9.8 NORTH AMERICA FMD VACCINE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 MULTIVALENT VACCINES

9.8.2 MONOVALENT VACCINES

9.9 NORTH AMERICA MULTIVALENT VACCINES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.9.1 ASIA-PACIFIC

9.9.2 EUROPE

9.9.3 NORTH AMERICA

9.9.4 SOUTH AMERICA

9.9.5 MIDDLE EAST AND AFRICA

9.1 NORTH AMERICA MONOVALENT VACCINES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.10.1 ASIA-PACIFIC

9.10.2 EUROPE

9.10.3 NORTH AMERICA

9.10.4 SOUTH AMERICA

9.10.5 MIDDLE EAST AND AFRICA

10 NORTH AMERICA FMD VACCINE MARKET, BY VACCINATION ROUTE

10.1 OVERVIEW

10.2 INTRAMUSCULAR

10.3 SUBCUTANEOUS

10.4 OTHERS

10.5 NORTH AMERICA INTRAMUSCULAR IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.5.1 ASIA-PACIFIC

10.5.2 EUROPE

10.5.3 NORTH AMERICA

10.5.4 SOUTH AMERICA

10.5.5 MIDDLE EAST AND AFRICA

10.6 NORTH AMERICA SUBCUTANEOUS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.6.1 ASIA-PACIFIC

10.6.2 EUROPE

10.6.3 NORTH AMERICA

10.6.4 SOUTH AMERICA

10.6.5 MIDDLE EAST AND AFRICA

10.7 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.7.1 ASIA-PACIFIC

10.7.2 EUROPE

10.7.3 NORTH AMERICA

10.7.4 SOUTH AMERICA

10.7.5 MIDDLE EAST AND AFRICA

11 NORTH AMERICA FMD VACCINE MARKET, BY ANIMAL TYPE

11.1 OVERVIEW

11.2 BOVINE

11.3 PORCINE

11.4 OVINE

11.5 CAPRINE

11.6 OTHERS

11.7 NORTH AMERICA BOVINE IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.7.1 ASIA-PACIFIC

11.7.2 EUROPE

11.7.3 NORTH AMERICA

11.7.4 SOUTH AMERICA

11.7.5 MIDDLE EAST AND AFRICA

11.8 NORTH AMERICA PORCINE IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.8.1 ASIA-PACIFIC

11.8.2 EUROPE

11.8.3 NORTH AMERICA

11.8.4 SOUTH AMERICA

11.8.5 MIDDLE EAST AND AFRICA

11.9 NORTH AMERICA OVINE IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.9.1 ASIA-PACIFIC

11.9.2 EUROPE

11.9.3 NORTH AMERICA

11.9.4 SOUTH AMERICA

11.9.5 MIDDLE EAST AND AFRICA

11.1 NORTH AMERICA CAPRINE IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.10.1 ASIA-PACIFIC

11.10.2 EUROPE

11.10.3 NORTH AMERICA

11.10.4 SOUTH AMERICA

11.10.5 MIDDLE EAST AND AFRICA

11.11 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.11.1 ASIA-PACIFIC

11.11.2 EUROPE

11.11.3 NORTH AMERICA

11.11.4 SOUTH AMERICA

11.11.5 MIDDLE EAST AND AFRICA

12 NORTH AMERICA FMD VACCINE MARKET, BY FORMULATION TYPE

12.1 OVERVIEW

12.2 LIQUID VACCINES

12.3 LYOPHILIZED (FREEZE-DRIED) VACCINES

12.4 OTHERS

12.5 NORTH AMERICA LIQUID VACCINES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.5.1 ASIA-PACIFIC

12.5.2 EUROPE

12.5.3 NORTH AMERICA

12.5.4 SOUTH AMERICA

12.5.5 MIDDLE EAST AND AFRICA

12.6 NORTH AMERICA LYOPHILIZED (FREEZE-DRIED) VACCINES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.6.1 ASIA-PACIFIC

12.6.2 EUROPE

12.6.3 NORTH AMERICA

12.6.4 SOUTH AMERICA

12.6.5 MIDDLE EAST AND AFRICA

12.7 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.7.1 ASIA-PACIFIC

12.7.2 EUROPE

12.7.3 NORTH AMERICA

12.7.4 SOUTH AMERICA

12.7.5 MIDDLE EAST AND AFRICA

13 NORTH AMERICA FMD VACCINE MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 ROUTINE PROPHYLACTIC VACCINATION

13.3 EMERGENCY VACCINATION (OUTBREAK CONTROL)

13.4 OTHERS

13.5 NORTH AMERICA ROUTINE PROPHYLACTIC VACCINATION IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.5.1 ASIA-PACIFIC

13.5.2 EUROPE

13.5.3 NORTH AMERICA

13.5.4 SOUTH AMERICA

13.5.5 MIDDLE EAST AND AFRICA

13.6 NORTH AMERICA EMERGENCY VACCINATION (OUTBREAK CONTROL) IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.6.1 ASIA-PACIFIC

13.6.2 EUROPE

13.6.3 NORTH AMERICA

13.6.4 SOUTH AMERICA

13.6.5 MIDDLE EAST AND AFRICA

13.7 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.7.1 ASIA-PACIFIC

13.7.2 EUROPE

13.7.3 NORTH AMERICA

13.7.4 SOUTH AMERICA

13.7.5 MIDDLE EAST AND AFRICA

14 NORTH AMERICA FMD VACCINE MARKET, BY END USER

14.1 OVERVIEW

14.2 COMMERCIAL LIVESTOCK FARMS

14.3 VETERINARY HOSPITALS

14.4 VETERINARY CARE CENTERS

14.5 VACCINATION CENTRES

14.6 OTHERS

14.7 NORTH AMERICA COMMERCIAL LIVESTOCK FARMS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.7.1 ASIA-PACIFIC

14.7.2 EUROPE

14.7.3 NORTH AMERICA

14.7.4 SOUTH AMERICA

14.7.5 MIDDLE EAST AND AFRICA

14.8 NORTH AMERICA VETERINARY HOSPITALS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.8.1 ASIA-PACIFIC

14.8.2 EUROPE

14.8.3 NORTH AMERICA

14.8.4 SOUTH AMERICA

14.8.5 MIDDLE EAST AND AFRICA

14.9 NORTH AMERICA VETERINARY CARE CENTERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.9.1 ASIA-PACIFIC

14.9.2 EUROPE

14.9.3 NORTH AMERICA

14.9.4 SOUTH AMERICA

14.9.5 MIDDLE EAST AND AFRICA

14.1 NORTH AMERICA VACCINATION CENTRES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.10.1 ASIA-PACIFIC

14.10.2 EUROPE

14.10.3 NORTH AMERICA

14.10.4 SOUTH AMERICA

14.10.5 MIDDLE EAST AND AFRICA

14.11 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.11.1 ASIA-PACIFIC

14.11.2 EUROPE

14.11.3 NORTH AMERICA

14.11.4 SOUTH AMERICA

14.11.5 MIDDLE EAST AND AFRICA

15 NORTH AMERICA FMD VACCINE MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT SALES (GOVERNMENT PROCUREMENT & TENDER SUPPLY)

15.3 RETAIL SALES

15.4 OTHERS

15.5 NORTH AMERICA DIRECT SALES (GOVERNMENT PROCUREMENT & TENDER SUPPLY) IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

15.5.1 ASIA-PACIFIC

15.5.2 EUROPE

15.5.3 NORTH AMERICA

15.5.4 SOUTH AMERICA

15.5.5 MIDDLE EAST AND AFRICA

15.6 NORTH AMERICA RETAIL SALES IN FMD VACCINE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

15.6.1 HOSPITAL PHARMACY

15.6.2 RETAIL PHARMACY

15.6.3 ONLINE PHARMACY

15.7 NORTH AMERICA RETAIL SALES IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

15.7.1 ASIA-PACIFIC

15.7.2 EUROPE

15.7.3 NORTH AMERICA

15.7.4 SOUTH AMERICA

15.7.5 MIDDLE EAST AND AFRICA

15.8 NORTH AMERICA OTHERS IN FMD VACCINE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

15.8.1 ASIA-PACIFIC

15.8.2 EUROPE

15.8.3 NORTH AMERICA

15.8.4 SOUTH AMERICA

15.8.5 MIDDLE EAST AND AFRICA

16 NORTH AMERICA FMD VACCINE MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 MEXICO

16.1.3 CANADA

17 NORTH AMERICA FMD VACCINE MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

18 SWOT ANALYSIS

19 COMPANY PROFILES

19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.

19.1.1 COMPANY SNAPSHOT

19.1.2 COMPANY SHARE ANALYSIS

19.1.3 PRODUCT PORTFOLIO

19.1.4 RECENT DEVELOPMENT

19.2 CEVA SANTÉ ANIMALE

19.2.1 COMPANY SNAPSHOT

19.2.2 COMPANY SHARE ANALYSIS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENT

19.3 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 INDIAN IMMUNOLOGICALS LTD.

19.4.1 COMPANY SNAPSHOT

19.4.2 COMPANY SHARE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENT

19.5 BIOGÉNESIS BAGÓ

19.5.1 COMPANY SNAPSHOT

19.5.2 COMPANY SHARE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 BIOVET PRIVATE LTD

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BRILLIANT BIO PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 DOLLVET

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 ENIMMUNE CORP.

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 JINYU BIOTECHNOLOGY CO., LTD.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 KENYA VETERINARY VACCINES PRODUCTION INSTITUTE

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 LIMOR DE COLOMBIA SAS

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 MEVAC FOR VACCINES

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 NATIONAL VETERINARY INSTITUTE

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 SHCHELKOVO BIOCOMBINAT

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 SHANGHAI SHEN LIAN BIOMEDICAL CORPORATION

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 VETAL S.A.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 VECOL

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 ZOETIS SERVICES LLC

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS